Scholarlink

<p>Rituximab (RTX) causes B‑cell depletion by binding to the CD20 antigen. A&#xa0;less well-known adverse drug reaction of RTX is late-onset neutropenia (LON), which occurs approximately 6&#xa0;months after treatment initiation. As clinical management, regular differential blood cell counts should be performed during RTX treatment. Besides a&#xa0;watch-and-wait strategy, supportive administration of granulocyte colony-stimulating factor (G-CSF) can be discussed for acute LON episodes. Re-exposure to RTX after LON has occurred is generally considered acceptable after diligent benefit-risk evaluation and thorough patient information. In this case series, we would like to present 2&#xa0;cases of rheumatology patients with severe LON after RTX administration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schwerwiegende Late-onset-Neutropenien nach Rituximab-Gabe

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Carla E. Schütte,
  • Christina Hillebrecht,
  • Jens G. Kuipers,
  • Dirk O. Stichtenoth,
  • Patrick-Pascal Strunz,
  • Johannes Heck

摘要

Rituximab (RTX) causes B‑cell depletion by binding to the CD20 antigen. A less well-known adverse drug reaction of RTX is late-onset neutropenia (LON), which occurs approximately 6 months after treatment initiation. As clinical management, regular differential blood cell counts should be performed during RTX treatment. Besides a watch-and-wait strategy, supportive administration of granulocyte colony-stimulating factor (G-CSF) can be discussed for acute LON episodes. Re-exposure to RTX after LON has occurred is generally considered acceptable after diligent benefit-risk evaluation and thorough patient information. In this case series, we would like to present 2 cases of rheumatology patients with severe LON after RTX administration.